GNSZ News and Video June 23, 2014 GenSpera, Inc
Post# of 7839
Posted On: 06/23/2014 8:43:00 AM
Re: WARMBUFFETT #91
GNSZ News and Video June 23, 2014
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer....
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select: cancer."
Chairman and CEO, Craig Dionne, PhD. says, "We have taken the powerful toxin thapsigargin and found a way to keep it inactive until it finds the cells it has been programmed to seek. Then it releases its active ingredient and destroys all of the targeted cells."
In the case of GenSpera's first drug, G-202, this target is PSMA, an enzyme which is only found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.
See the Video:
http://youtu.be/jULjEul-mBk
Chairman and CEO, Craig Dionne, PhD., will be presenting at the 2014 BIO International Convention on Tuesday, June 24th at 11:15 PDT in San Diego, CA, where he will be providing an update on G-202. The Company's BIO presentation will be available on June 24th to investors.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website:
www.genspera.com or follow us on Twitter @GenSperaNews.
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer....
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select: cancer."
Chairman and CEO, Craig Dionne, PhD. says, "We have taken the powerful toxin thapsigargin and found a way to keep it inactive until it finds the cells it has been programmed to seek. Then it releases its active ingredient and destroys all of the targeted cells."
In the case of GenSpera's first drug, G-202, this target is PSMA, an enzyme which is only found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.
See the Video:
http://youtu.be/jULjEul-mBk
Chairman and CEO, Craig Dionne, PhD., will be presenting at the 2014 BIO International Convention on Tuesday, June 24th at 11:15 PDT in San Diego, CA, where he will be providing an update on G-202. The Company's BIO presentation will be available on June 24th to investors.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website:
www.genspera.com or follow us on Twitter @GenSperaNews.
(0)
(0)Scroll down for more posts ▼